Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study

Leukemia. 2001 Nov;15(11):1803-4. doi: 10.1038/sj.leu.2402274.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Acute Disease
  • Antineoplastic Agents / therapeutic use
  • Bias*
  • Clinical Trials as Topic
  • Data Interpretation, Statistical
  • Doxorubicin / therapeutic use
  • Humans
  • Idarubicin / therapeutic use
  • Leukemia, Myeloid / drug therapy*
  • Odds Ratio

Substances

  • Antineoplastic Agents
  • Doxorubicin
  • Idarubicin